Springer Nature
Browse
12885_2018_4308_MOESM8_ESM.docx (13.27 kB)

Additional file 8: of Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Download (13.27 kB)
journal contribution
posted on 2018-04-05, 05:00 authored by Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang, Ming Kuang
Table S7. References used to derive monthly mortality of patients with compensated cirrhosis and progressive HCC after TACE. (DOCX 13 kb)

Funding

the National Natural Science Foundation of China

History

Usage metrics

    BMC Cancer

    Categories

    Keywords

    SorafenibTransarterial chemoembolizationAdvanced-stage hepatocellular carcinomaCost-effectiveness analysisMarkov model

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC